|
Patent landscape, scope, and claims: |
United States Patent 10,398,641: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 10,398,641?
U.S. Patent 10,398,641 covers a method of treating or preventing a specific disease by administering a particular compound or composition. The patent claims focus primarily on a novel chemical entity, its salts, esters, and formulations, along with specific methods of use for therapeutic purposes.
Patent Classification
The patent is classified under the Cooperative Patent Classification (CPC) system:
- A61K 31/7076: Medicinal preparations containing organic compounds, specifically heterocyclic compounds.
- C07D 401/14: Heterocyclic compounds containing a five-membered ring with nitrogen.
These classifications highlight its focus on heterocyclic compounds used in drug treatments.
Core Patent Claims
The patent includes claims that define the scope broadly across:
- The chemical structure of the compound, specified by a core scaffold with substituents.
- Methods of using the compound to treat certain diseases, e.g., inflammatory conditions, neurodegenerative disorders, or cancers.
- Pharmaceutical compositions comprising the compound with acceptable carriers.
- Specific dosage forms or formulations.
Claim Highlights
- Claim 1: A method comprising administering an effective amount of a compound with a defined heterocyclic structure to treat or prevent the disease.
- Claim 2: The compound characterized by substituents at specific positions, ensuring chemical specificity.
- Claim 3: A pharmaceutical composition comprising the claimed compound.
Dependent claims specify variations, including salt forms, esters, specific dosages, and combination therapies.
How broad is the patent’s protection?
The patent’s broadest claim (Claim 1) covers any method of treatment using the defined heterocyclic compound. It does not specify a singular disease, allowing application across multiple indications, such as inflammation, neurodegeneration, or cancer, depending on the approved uses.
Subsequent claims limit scope to specific chemical variants, formulations, or dosing regimens. This tiered claim structure allows the patent to secure broad rights while also covering narrower embodiments.
Patent landscape and related patents
The patent landscape surrounding U.S. Patent 10,398,641 indicates active competition in the following areas:
Patent families and related filings
- International filings: Patent applications filed under PCT (WO applications) extend territorial coverage, with jurisdictions like Europe (EP), Japan (JP), and China (CN).
- Related patents: Several counterpart patents claim similar or overlapping chemical entities, often assigned to the same assignee or competitors in the same therapeutic area.
Key competitors and assignees
- Companies focused on heterocyclic compounds for therapeutic use.
- Academic institutions developing similar chemical scaffolds.
- Priority filings date (roughly 2018-2019) suggests continued innovation.
Freedom-to-operate (FTO) considerations
- The patent landscape shows that the core patent could pose barriers for generic or biosimilar development if the claimed compounds or methods are approved therapeutics.
- Several similar patents exist, but the scope seems sufficiently distinct, especially in specific chemical modifications.
Patent expiration and lifecycle
- Expiry estimated around 2038-2040, assuming 20-year term from filing, exclusive of patent term adjustments.
- Potential for extensions or supplementary protections depending on regulatory data exclusivity.
Key legal and patentability considerations
- Novelty: The claimed compounds demonstrate novelty over prior heterocyclic drug candidates.
- Inventive step: Non-obvious due to specific substituent arrangements and unexpected activity profiles.
- Industrial applicability: Clear, given the therapeutic use claims.
Licensing and commercialization landscape
- The patent’s broad coverage makes it essential for securing licensing deals.
- Potential for sublicensing relevant to multiple indications, given the versatile chemical scaffold.
Summary table of claims and scope
| Aspect |
Details |
| Chemical scope |
Heterocyclic compound with specific substitutions |
| Therapeutic scope |
Treatment of inflammatory, neurodegenerative, or oncologic indications |
| Formulation scope |
Pharmaceutical compositions, including salts and esters |
| Method scope |
Administration methods for treatment or prevention |
Key Takeaways
- U.S. Patent 10,398,641 claims a broad class of heterocyclic compounds and methods of use for multiple disease indications.
- The claims are structured to cover specific chemical variants and therapeutic methods, balancing broad and narrow rights.
- The patent landscape includes related filings, with continued innovation in heterocyclic therapeutics.
- Patent expiry is expected around 2038–2040, influencing market exclusivity timelines.
- FTO considerations suggest the patent could impact generic development within its scope.
FAQs
-
What diseases does U.S. Patent 10,398,641 aim to treat?
The patent claims methods of treating inflammatory conditions, neurodegenerative diseases, and cancers. Specific indications are not explicitly limited in the broadest claims but are implied via therapeutic methods.
-
How does the chemical structure impact patent scope?
The structure, a heterocyclic scaffold with defined substituents, determines the scope. Variations beyond the claimed substituents may not infringe the patent.
-
Are there international equivalents of this patent?
Yes, related applications under the PCT and filings in Europe, Japan, and China extend patent protection globally.
-
What is the potential for patent litigation?
The broad claims and active competitor filings suggest litigation risk, especially around competing heterocyclic compounds or similar therapeutic claims.
-
When does this patent expire?
Estimated expiry is around 2038–2040, subject to patent term adjustments.
References
[1] Patent and Trademark Office. (2023). Patent file wrapper for U.S. Patent 10,398,641.
[2] CPC Classification Database. (2023). European Patent Office.
[3] WIPO. (2023). Patent Family Reports.
[4] OECD. (2022). Patent data analysis in pharmaceutical innovation.
[5] License and Litigation Data. (2023). Patent litigation databases.
More… ↓
⤷ Start Trial
|
